DILPACIMAB
UNII F27LAH6D5O

Substance Identification & Data

This profile provides standardized clinical and technical data for Dilpacimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) F27LAH6D5O.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1791420-09-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

F27LAH6D5O

CAS Registry Number

1791420-09-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

DILPACIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C116750

National Cancer Institute reference terminology for clinical and research data.

INN ID

10863

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

GH-95

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Dilpacimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

DILPACIMAB

Common Names & Synonyms

DILPACIMAB [INN]

DILPACIMAB [USAN]

DILPACIMAB [WHO-DD]

IMMUNOGLOBULIN, ANTI-(NOTCH LIGAND DLL4/VASCULAR ENDOTHELIAL GROWTH FACTOR) (SYNTHETIC HUMAN PR-1283233 HEAVY CHAIN), DISULFIDE WITH SYNTHETIC HUMAN PR-1283233 LIGHT CHAIN, DIMER

Systematic Nomenclature

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS DELTA-LIKE PROTEIN 4 (DROSOPHILA DELTA HOMOLOG 4, DELTA4)) AND ANTI-(HOMO SAPIENS VASCULAR ENDOTHELIAL GROWTH FACTOR A (VASCULAR PERMEABILITY FACTOR, VEGF-A, VPF)), DUAL VARIABLE DOMAIN HUMANIZED MOUSE MONOCLONAL ANTIBODY, BISPECIFICDUAL VARIABLE .GAMMA.1 HEAVY CHAIN (1-577) (HUMANIZED VH ANTI-DELTA4 (HOMO SAPIENS IGHV3-48*01 (90%) (IGHD)-IGHJ4*01 (93%)) (8.8.11) (1-118)-IGHG1*03-(1-6)-PEPTIDE (119-124) HUMANIZED VH ANTI-VEGF-A (HOMO SAPIENS IGHV3-30*02 (77%) (IGHD)-IGHJ4*01 (93%)) (8.9.16) (125-247)-HOMO SAPIENS IGHG1*03 (CH1(R97>K(344)), CH2(L4>A(364), L5>A(365))) (248-577)) (350-334')-DISULFIDE WITH DUAL VARIABLE .KAPPA. LIGHT CHAIN (1'-334') (HUMANIZED V-KAPPA ANTI-DELTA4 (HOMO SAPIENS IGKV1D-13*01 (88%) IGHJ2*01) (6.3.9) (1'-107')-IGKC*01-(1-13)-PEPTIDE (108'-120') HUMANIZED V-KAPPA ANTI-VEGF-A (HOMO SAPIENS IGKV1-16*01 (88%) IGHJ1*01) (6.3.9) (121'-227')-HOMO SAPIENS IGKC*01 (228'-334')), DIMER (356-356'':359-359'')-BISDISULFIDE

SYS